Overcoming hurdles in cell and gene therapy commercialization
By World Courier
Cell and gene therapies (CGTs) represent one of the most promising frontiers in modern medicine. As of the second quarter of August 2026, globally there are 159 approved advanced therapies — including cell, gene, and RNA-based treatments — yet the pipeline of candidates in development remains extensive, with hundreds of agents across clinical and pre-clinical stages in the United States alone.1 Despite this momentum, the gap between pipeline activity and approval rates remains wide, reflecting just how demanding the path to market truly is.
The challenges hindering approval are not simply scientific. They span economic barriers, operational complexity, and an evolving regulatory environment that continues to place significant demands on therapy developers.
This article explores what cell and gene therapy commercialization involves, the key aspects developers must navigate, and the main challenges that arise along the way — and how the right logistics partner can help overcome them. From temperature control and cryogenic packaging to regulatory compliance and supply chain visibility, specialized logistics plays a central role in maximizing the chances of bringing CGTs successfully to market.
Learn more about our cell and gene therapy solutions.
What is cell and gene therapy commercialization?
Cell and gene therapy commercialization is the process of taking an innovative therapy from clinical trials through to the market, and ensuring it reaches patients securely. Unlike traditional pharmaceuticals, CGTs often rely on living biological materials or genetically modified cells, which means the commercialization journey is far more complex. It requires coordinating manufacturing, regulatory approval, reimbursement strategy, and specialized logistics — all simultaneously, and with little margin for error.
What are the key aspects of cell and gene therapy commercialization?
Supply chain and logistics
CGTs are fundamentally different from mass-produced drugs. Many are derived from a patient's own cells or depend on sensitive biological materials that must be maintained at precise temperatures throughout transit. Because each therapy is effectively unique, commercialization depends on rigorous tracking of chain of identity (COI) and chain of custody (COC) — ensuring that the right therapy reaches the right patient at the right time, without any break in integrity.
Moving from small-scale to commercial-scale manufacturing
Scaling from small clinical batches to full commercial production is one of the most operationally demanding stages of cell and gene therapy commercialization. It requires good manufacturing practice (GMP)-compliant processes that can sustain consistent quality at volume. This is a significant leap from the controlled environments of early-phase trials.
Pricing and reimbursement
Because of the high upfront costs involved in cell and gene therapy manufacturing and commercialization, pharmaceutical companies frequently work with insurers and government bodies — such as the Centers for Medicare & Medicaid Services (CMS) — to design outcomes-based payment models. These tie a therapy's cost to its clinical success, with refunds or structured annuities provided if the treatment fails to meet pre-specified patient health outcomes.
Patient access and education
Bringing a CGT to market is not only a logistical and regulatory challenge. it is also a communications one. Educating patient communities and healthcare providers about the administration, risks, and benefits of these treatments is a core component of successful cell and gene therapy commercialization, particularly for therapies targeting rare or underserved conditions.
What are the main challenges of cell and gene therapy commercialization?
Unique scientific challenges in cell and gene therapy commercialization
The development and commercialization of CGTs are hindered by unique scientific challenges that stem from their innovative nature and the complexities of manipulating genetic material and cells. These challenges set CGTs apart from traditional pharmaceutical products and contribute to low approval rates.
Need for personalized treatments
CGTs are often tailored to the individual patient, necessitating careful tracking and specialized handling throughout the logistics process. This personalized approach creates unique logistical demands that require robust quality assurance measures to maintain the integrity of these innovative therapies.
Patient variability
Patient-specific biological factors can influence the efficacy of CGTs, making it difficult to establish standardized and safe treatment protocols. This results in challenges when conducting clinical trials, with patient selection and stratification being essential for maximizing outcomes.
Potential immune reactions
The potential for immune reactions to allogeneic cells or viral vectors adds another layer of complexity. Managing immune reactions is critical to CGT success, requiring specialized expertise and careful monitoring to ensure treatment safety and efficacy.
Financial hurdles in cell and gene therapy commercialization
The development and commercialization of CGTs are often hindered by economic hurdles that can limit patient access or even deter companies from pursuing these innovative treatments.
High development and manufacturing costs
The high cost of development and manufacturing creates economic challenges, often resulting in hefty price tags. This, coupled with complex reimbursement models, can affect the broader landscape of cell and gene therapy manufacturing and commercialization, and ultimately hinder patient access.
Cost-effectiveness and value proposition concerns
As a result of high development and manufacturing costs, CGTs are often the most expensive therapeutics available. This is evidenced by the approval of Lenmeldy — a gene therapy with a price tag of US$4.3 million — raising concerns from payers and healthcare systems about the cost-effectiveness and value proposition of CGTs compared to alternative treatments. This evaluation is particularly challenging for therapies targeting rare diseases or conditions with limited existing options.
Reimbursement and access challenges
Ensuring adequate reimbursement and access to CGTs is a major economic challenge that requires collaboration among therapy developers, payers, and policymakers. Developing innovative payment models — such as outcome-based pricing or annuity-based reimbursement — can help distribute the high upfront costs over time and align payments with the long-term benefits of these therapies. By addressing these economic hurdles, CGT developers and stakeholders can pave the way for increased patient access and long-term treatment sustainability.
Operational and regulatory obstacles in CGT commercialization
In addition to the scientific and economic challenges, cell and gene therapy commercialization faces operational and regulatory obstacles that must be addressed to facilitate the successful development and approval of these innovative treatments.
Evolving regulatory landscape
The regulatory landscape for CGTs is constantly evolving, and there is a growing need for clear and harmonized regulations to facilitate the commercialization of these therapies. Regulatory agencies must strike a balance between ensuring patient safety and fostering innovation, while also providing clear guidance to therapy developers on the requirements for approval. Navigating intricate CGT regulatory requirements is crucial for ensuring product quality, safety, and compliance throughout the supply chain.
Logistical complexities
The CGT supply chain is inherently complex, with numerous potential points of failure. The nuanced differences between autologous and allogeneic approaches highlight the sourcing and processing challenges involved in these therapies.
Autologous therapies require careful tracking and handling to maintain the integrity of the personalized treatment. Allogeneic therapies can be manufactured in bulk but may require additional measures to mitigate the risk of immune rejection and ensure consistent quality across batches. The decisions made by therapy developers regarding temperature control and packaging are also critical — many CGTs require cryogenic transportation and storage to maintain the viability and potency of living cells or genetic material.
The role of specialized logistics in overcoming challenges
Amidst the multifaceted challenges hindering cell and gene therapy commercialization, specialized logistics providers play an indispensable role in addressing logistical complexities and facilitating the successful delivery of these innovative treatments to patients. Partnering with a specialized logistics provider offers tailored solutions to mitigate risks across a diverse and nuanced set of modalities, guide navigation of regulatory hurdles, and facilitate bringing CGTs to market.
Temperature control and packaging
Temperature control is paramount in the CGT supply chain, as even minor deviations can compromise the viability and potency of these living therapies. A specialized cryogenic transportation partner can offer innovative solutions — including advanced cryogenic shipping containers, temperature monitoring systems, and customized packaging configurations — to ensure the integrity of these temperature-sensitive products throughout the supply chain.
Explore World Courier's temperature control solutions.
Regulatory compliance and supply chain visibility
Navigating the regulatory landscape is crucial to successful cell and gene therapy commercialization. Specialized providers have deep expertise in regulatory compliance — including (GMP) and good distribution practice (GDP) standards — ensuring adherence throughout the supply chain. They also offer real-time visibility and tracking solutions that enhance transparency and traceability from manufacturer to patient.
Learn more about our compliance approach.
Alternative solutions and infrastructure readiness
Collaboration between therapy developers, specialized logistics providers, and healthcare facilities is crucial to ensure infrastructure readiness and the seamless integration of logistics solutions into the supply chain. This may involve:
- Centralizing the manufacturing of allogeneic CGTs to help reduce costs and improve efficiency
- Point-of-care or regional manufacturing to reduce long-distance transportation requirements and improve access for patients in remote areas
- Establishing regional storage centers equipped with the necessary temperature control and monitoring systems to maintain CGT integrity throughout the supply chain
- Leveraging alternative transportation modes — such as dedicated charter flights or ground transportation — to ensure timely and secure delivery
- Ensuring the availability of specialized shippers at regional distribution hubs with cryogenic filling stations.
- Sharing best practices for import/export and airline handling processes, including support for risk assessments covering potential dangerous goods classifications and airport security scan exemptions
Mitigating risks and navigating regulatory hurdles
By partnering with specialized logistics providers, CGT developers can significantly reduce the risks associated with transporting and handling these sensitive therapies. The result is increased chances of successful commercialization and regulatory approval.
Removing roadblocks to CGT breakthroughs with effective logistics
Addressing the multifaceted challenges hindering the approval of cell and gene therapy commercialization requires a holistic approach that considers the many contributing scientific, economic, and logistical factors. While scientific refinement is crucial for improving treatment approaches, the high costs associated with CGT development and manufacturing pose significant barriers to widespread accessibility — areas where effective logistics solutions can pay real dividends. Tailored logistics in transportation and distribution also plays a central role in mitigating risks and navigating regulatory hurdles, ultimately helping to improve CGT approval rates.
As the CGT industry continues to evolve, therapy developers, logistics providers, regulatory bodies, and other stakeholders must work together to address the challenges hindering the widespread adoption of these transformative therapies. By leveraging the expertise of specialized logistics providers and fostering a genuinely collaborative approach, the industry can open a clearer path toward the successful commercialization of life-changing treatments.
As a leading provider of specialized logistics solutions for the CGT industry, World Courier is at the forefront of addressing the challenges that stand between an innovative therapy and the patients who need it. Our team offers tailored solutions for the seamless and secure delivery of CGTs worldwide. With cutting-edge technologies and deep expertise, we help developers navigate hurdles and facilitate successful commercialization. Contact us to explore how our comprehensive logistics solutions can streamline your development journey.
Cell and gene therapy commercialization FAQs
Is gene therapy commercially viable?
Yes — gene therapy is commercially viable, and there are clear signs of progress. High-value curative therapies are reaching patients, and some treatments are beginning to expand into broader markets as clinical evidence matures. That said, significant challenges remain. High development costs, low patient volumes, and hesitancy from payers and reimbursement bodies can make the path to sustainable commercialization a difficult one. Commercial viability ultimately depends on how well developers address these financial and logistical realities alongside the science.
What makes cell and gene therapies harder to commercialize than traditional drugs?
Several factors combine to make CGTs considerably more complex to bring to market. Many use living cells or viral vectors, which demand 'just-in-time' supply chains with no tolerance for temperature deviations or delays. The upfront costs of development and manufacturing are substantial, and the long-term durability of a single-dose therapy is often still uncertain at the point of approval — making it harder to justify the price to payers. Add to this the strict scrutiny applied by regulatory bodies and the hesitancy of insurers to commit to outcomes they cannot yet predict, and it becomes clear why cell and gene therapy commercialization requires a fundamentally different commercial strategy from traditional pharmaceuticals.
References
